# Palisade Bio Inc. (PALI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.09, market value $364 million.

## Valuation
- **P/E (trailing): 3.2×**. Palisade Bio Inc. trades at 3.2× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 728.5×**. Each dollar of revenue is priced at 728.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.0×**. The shares trade at 3.0× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 31.1%**. The inverse of the P/E: 31.1% of the price is earned each year.

## Profitability
- **Return on equity: -13.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 697.3%**. Return on all capital, debt included, is 697.3%: comfortably above what that capital costs.
- **Return on assets: -23.8%**. Each dollar of assets produces -23.8% of profit.

## Growth
- **EPS growth (1 yr): 97.1%**. Earnings per share rose 97.1%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 3.8×**. It would take 3.8 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 28.95** (quick 28.95). Current assets cover the next year's liabilities 28.95 times.
- **Altman Z-score: 46.09**. A Z-score of 46.09 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Palisade Bio Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 231.7%** (YTD -11.1%, 3-mo 20.1%). The shares are up 231.7% over twelve months including dividends.
- **From 52-week high: -26.9%** (294.3% above the low). Trading 27% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.30** (volatility 114%). Beta of 1.30 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PALI · Page: https://foliofundamentals.com/stocks/pali

Not investment advice.